For research use only. Not for therapeutic Use.
Omesdafexor is a FXR agonist. Omesdafexor can be used in the research of liver disease or a metabolic inflammation-mediated disease[1][2].
| Catalog Number | I043394 |
| CAS Number | 2244440-85-3 |
| Synonyms | N-[3-(1-cyclopropylpyrazol-4-yl)phenyl]-4-hydroxy-N-[[4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]cyclohexane-1-carboxamide |
| Molecular Formula | C34H43N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C34H43N3O3/c1-23-18-28(12-17-33(23)40-2)25-8-6-24(7-9-25)21-36(34(39)26-10-15-32(38)16-11-26)31-5-3-4-27(19-31)29-20-35-37(22-29)30-13-14-30/h3-5,12,17-20,22,24-26,30,32,38H,6-11,13-16,21H2,1-2H3 |
| InChIKey | RPBNLMPTFCTXRQ-UHFFFAOYSA-N |
| SMILES | CC1=C(C=CC(=C1)C2CCC(CC2)CN(C3=CC=CC(=C3)C4=CN(N=C4)C5CC5)C(=O)C6CCC(CC6)O)OC |
| Reference | [1]. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf?sfvrsn=8544ca1e_3&download=true [2]. Song, Kenneth, et al. Farnesoid X receptor agonists for the treatment of a liver disease or a metabolic inflammation-mediated disease or disorder. Patent WO2020061114. |
